SG/CALL/NOVO-NORDISK B/1200/0.1/19.12.25 | Market Closed - Boerse Frankfurt Warrants 01:08:22 23/05/2024 am IST | ||
| 1.4 EUR | -2.78% |
|
| Current month | -3.45% | ||
| 1 month | +2.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 1.4 | -2.78% |
| 21/24/21 | 1.44 | +4.35% |
| 20/24/20 | 1.38 | +3.76% |
| 17/24/17 | 1.33 | -4.32% |
| 16/24/16 | 1.39 | -2.11% |
Real-time Boerse Frankfurt Warrants
Last update May 23, 2024 at 01:08 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9B0C |
| ISIN | DE000SU9B0C0 |
| Date issued | 14/02/2024 |
| Strike | 1,200 kr |
| Maturity | 19/12/2025 (576 Days) |
| Parity | 10 : 1 |
| Emission price | 1.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.79 € |
|---|---|
| Lowest since issue | 1.04 € |
| Spread | 0.05 € |
| Spread % | 3.42% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Warrants
- Warrant
